A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Some medtech stocks did decline in 2018, but many more increased in value.
Big cap medtech disappoints – but still beats pharma.
Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.